Comprehensive inhibition of PI3K-AKT-mTOR signalling with the combination of mTORC1/2 and PI3Kβ inhibitors is effective in DLBCL cell lines of different subtypes [8, 29]. Here, AKT1 is linked to diffuse large B-cell lymphoma.